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Abstract
The MDM2 proto-oncogene plays a key role in central cellular processes like growth control and apoptosis, and the gene
locus is frequently amplified in sarcomas. Two polymorphisms located in the MDM2 promoter P2 have been shown to affect
cancer risk. One of these polymorphisms (SNP309T.G; rs2279744) facilitates Sp1 transcription factor binding to the
promoter and is associated with increased cancer risk. In contrast, SNP285G.C (rs117039649), located 24 bp upstream of
rs2279744, and in complete linkage disequilibrium with the SNP309G allele, reduces Sp1 recruitment and lowers cancer risk.
Thus, fine tuning of MDM2 expression has proven to be of significant importance with respect to tumorigenesis. We
assessed the potential functional effects of a third MDM2 promoter P2 polymorphism (SNP344T.A; rs1196333) located on
the SNP309T allele. While in silico analyses indicated SNP344A to modulate TFAP2A, SPIB and AP1 transcription factor
binding, we found no effect of SNP344 status on MDM2 expression levels. Assessing the frequency of SNP344A in healthy
Caucasians (n = 2,954) and patients suffering from ovarian (n = 1,927), breast (n = 1,271), endometrial (n = 895) or prostatic
cancer (n = 641), we detected no significant difference in the distribution of this polymorphism between any of these cancer
forms and healthy controls (6.1% in healthy controls, and 4.9%, 5.0%, 5.4% and 7.2% in the cancer groups, respectively). In
conclusion, our findings provide no evidence indicating that SNP344A may affect MDM2 transcription or cancer risk.
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Introduction
The Mouse Double Minute 2 homolog (MDM2) is a key
regulator of p53 as well as retinoblastoma protein function [1,2,3].
Thus, elevated MDM2 protein levels due to MDM2 gene
amplification or other mechanisms have been regarded as an
alternative to TP53 mutations diminishing p53 function in many
human cancers [2,4,5,6,7].
In 2004 the group of A. Levine discovered a polymorphism
SNP309T.G (rs2279744) in the MDM2 intronic P2 promoter [8].
SNP309G enhances MDM2 expression levels by increasing Sp1
transcription factor binding and was subsequently shown to be
associated with increased risk and an early age at diagnosis of
several malignancies [8,9,10].
While subsequent studies have confirmed an association
between SNP309G and the risk of multiple cancer forms, the
effect of this SNP seems to differ between ethnic groups: Thus,
while most studies performed in Asian or Ashkenazi Jewish
populations reports the SNP309G variant to enhance cancer risk
many studies conducted in Caucasian populations have failed to
reproduce a similar effect [11,12].
Recently, we reported a second polymorphism, SNP285G.C
(rs117039649), located 24 base-pairs from SNP309 in the MDM2
P2 promoter. The SNP285C variant allele is observed among
Caucasians only, in whom it forms a distinct SNP285C/309G
haplotype accounting for about 12% of the SNP309G alleles [13].
SNP285C antagonizes the effect of SNP309G by reducing Sp1
transcription factor binding strength to the MDM2 promoter and
is associated with a reduced risk for breast, ovarian and
endometrial cancers [13,14].
Taken together, the data from the studies on SNP309 and
SNP285 strongly indicate fine tuning of MDM2 P2 promoter
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e36263
activity to be of importance for cancer risk. It is therefore of
interest to search for additional variants in the MDM2 promoter
that may contribute to altered cancer risk.
SNP344T.A (rs1196333), located 35 base pairs downstream of
SNP309, was initially identified by Bond et al [8] in 4 out of 50
healthy individuals. Here, we present the first report assessing the
impact of SNP344 status on MDM2 expression as well as cancer
risk in large populations. Thus, we have examined its impact on
the risk of ovarian, breast, endometrial and prostate cancer, and
studied the same patient cohorts for which the risk profiles linked
to SNP309T.G and SNP285G.C have previously been analysed
in detail [13,14].
Materials and Methods
MDM2 promoter SNP344 status screening
A region of theMDM2 promoter P2 containing SNP344 (as well
as SNP285 and SNP309) was previously amplified by PCR,
sequenced and analysed for SNP285 and SNP309 status [13,14].
Here, these sequence traces were analysed for SNP344 status.
In silico predictions
Predictions of potential transcription binding sites in the MDM2
promoter affected by SNP344 status were performed using the
JASPAR database at http://jaspar.genereg.net [15]. Input
sequences for the predictions were tgcctgtcgggtca for the SNP344T-
allele and tgcctgacgggtca for the SNP344A-allele. Profile score
threshold were set to 80% (default settings).
MDM2 expression analysis
Total RNA was extracted from white blood cells drawn from
215 young males as part of a routine test during conscription in the
Navy [13] using Trizol reagent (Life technologies) according to the
manufacture’s protocol, and dissolved in DEPC treated ddH2O.
Single strand cDNA synthesis was performed using 500 ng total
RNA, oligo-dT- and random hexamer primers (Sigma) with
Transcriptor Reverse Transcriptase (Roche) in accordance with
the manufacturer’s instructions. After RT-PCR the cDNA was
diluted 1:10 in ddH2O.
Quantitative PCRs for total MDM2 expression levels, MDM2
promoter 2 specific expression and RPLP2 (internal reference)
were carried out using Hydrolysis probes (TIB MOLBIOL) on a
Ligthcycler 480 instrument (Roche). The following primers were
used: MDM2_F; aacatgtacctactgatggtgc, MDM2_R;
cagggtctcttgttccgaagc, MDM2_TM; 6FAM-aaccacctcacagattcc-
BBQ, MDM2P2_S; gcgattggagggtagacctgt, MDM2P2_R: ggtattg-
cacatttgcctggat, MDM2P2_TM; 6FAM-agtggcgtgcgtccgtgcc-
BBQ, RPLP2_F; gaccggctcaacaaggttat, RPLP2_A; ccccaccag-
caggtacac and RPLP2_TM; 6FAM-agctgaatggaaaaaacattgaa-
gacgtc-BBQ. Amplifications were performed in a reaction volume
of 10 ml using the LigthCyclerH 480 Probes Master kit (Roche)
with 0,5 mM of forward and reverse primer, 0,125 mM of each
hydrolysis probe and 3 ml cDNA. The thermocycling conditions
were: 5 min initial denaturation at 95uC, before 45 cycles at 95uC
for 10 s and at 55uC for 20 s, and a final cooling step at 40uC for
10 s. Relative MDM2 mRNA concentrations were calculated
based on in-run standard curves and normalization to RPLP2
mRNA levels in the same samples. Water was included in each run
as negative control and all analyses were performed in triplicate
runs.
Healthy Caucasian controls
The distribution of MDM2 SNP344 among cancer patients was
compared to 2,954 Norwegian healthy controls. The controls have
been described in detail previously [13,14].
African American individuals
DNA from African American individuals (n = 50) was purchased
from Coriell Institute for Medical Research (Cat # HD50AA).
Cancer patients
Ovarian (n= 1,927), breast (n = 1,271), endometrial (n = 895)
and prostate cancer patients (n = 641) were from patient cohorts
that were previously analysed for MDM2 SNP285 and SNP309
[13,14].
Ethics Considerations
Collection and use of samples from cancer patients and healthy
controls, as well as controls for expression analyses, was approved
by the Regional Ethical Committees of Western Norway (Hauke-
land University Hospital), Central Norway (Norwegian University
of Science and Technology), and South-Eastern Norway (Oslo
University Hospital Radiumhospitalet; Norwegian samples), and
The Medical Ethical Committees of the Leiden University
Medical Center, Leiden, The Netherlands, and the Erasmus
MC-Daniel den Hoed Cancer Center Rotterdam, The Nether-
lands (Dutch samples). All participants gave written informed
consent.
Statistical analysis
Expression levels of MDM2 between individuals with the
different genotypes of SNP344 were compared using the Mann-
Whitney rank test. Among individuals for whom MDM2
expression was analysed (n= 215), one harboured the SNP344AA
genotype. For statistical calculations, this individual was included
in the SNP344TA group and compared to the SNP344TT group.
Potential differences in the distribution of SNP344 between
cancer patients and healthy controls as well as between subgroups
of each cancer form were assessed by Odds Ratios (OR) and by
Fischer exact test. ORs are given with 95% confidence intervals
(CI).
Potential differences in age at onset of disease between the
patients were assessed by Kruskal-Wallis rank tests.
Survival was assessed by Kaplan–Meier analyses where the
different patients groups were compared using the log rank test;
deaths for reasons other than breast cancer were censored.
All p-values are two-sided, and p-values estimated by Fischer
exact tests are cumulative. All statistical analyses were performed
using the SPSS/PASW (version 15.0.1 and 17) software package.
Results
SNP344: Haplotype status and ethnic distribution
SNP344 (rs1196333) is located within the MDM2 promoter P2,
344 bps downstream of exon 1 (Figure 1). Among 2,954 healthy
Norwegian controls, we observed the SNP344A-variant in 181
individuals (6.1%). One individual harboured the homozygous
SNP344AA genotype, while 180 were heterozygous (SNP344TA;
Table 1). Thus, the minor allele frequency was 3.1%, and the
distribution of genotypes was in accordance with Hardy-Weinberg
equilibrium.
Notably, we observed the SNP344A-variant only among
individuals harbouring the SNP309TT or TG genotype, strongly
indicating SNP344A to be located on the SNP309T-allele, making
MDM2 Promoter SNP344T.A and Cancer Risk
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a distinct SNP309T/344A haplotype (p,1610210). Further, since
SNP285C is located on the SNP309G-allele, one may deduce that
SNP344A only exist in the SNP285G/309T/344A haplotype.
In a cohort of African Americans (n = 50) we found 17 (34%)
individuals to harbour SNP344A (one homozygous and 16
heterozygous). This frequency was significantly higher as com-
pared to the frequency observed among Caucasians (p,0.001).
Notably, the distribution of SNP344 among African Americans
was in line with the limited data on this SNP presented in the
Ensembl database. As for Caucasians, we found the SNP344A-
allele only among African Americans harbouring the SNP309T-
allele.
Effect of SNP344 status on transcription factor binding
In order to evaluate the potential impact of SNP344 status on
transcription factor binding, we performed in silico analyses using
the JASPAR database [15], predicting transcription factor binding
to the SNP344T and A-alleles. Using the ‘‘wild-type’’ SNP344T-
allele sequence and a profile score threshold of 80% (default
settings) in the database search, two transcription factor binding
sites were identified including the position of SNP344: one binding
site for TFAP2A and one for SPIB (Table 2). When substituting
the SNP344T with the A-variant, the predicted binding strength of
TFAP2A was slightly increased while the site for SPIB was
disrupted. In addition, introduction of the A generated a novel
binding site for AP1. Thus, transcription efficacy from the A-allele,
as compared to the T-allele, could either be reduced due to a
Figure 1. MDM2 promoter P2. (A) The promoter is located between exon 1 and 2 of the MDM2 gene and harbours SNP285 (rs117039649), SNP309
(rs2279744) and SNP344 (1196333). (B) Representative sequencing chromatogram from an individual heterozygous for SNP344 (sequence showed as
reverse complementary to the sense strand).
doi:10.1371/journal.pone.0036263.g001
Table 1. Distribution of SNP344 genotypes in cancer patients and healthy controls.
SNP344 (rs1196333) status
Cohort Genotype TT Genotype TA Genotype AA Total
n (%) n (%) n (%) n (%)
Ovarian cancer 1831 (95.0) 95 (4.9) 1 (0.1) 1927 (100)
Breast cancer 1205 (94.8) 63 (5.0) 3 (0.2) 1271 (100)
Endometrial cancer 845 (94.4) 48 (5.4) 2 (0.2) 895 (100)
Prostatic cancer 594 (92.7) 46 (7.2) 1 (0.2) 641 (100)
Healthy controls 2773 (93.9) 180 (6.1) 1 (0.0) 2954 (100)
doi:10.1371/journal.pone.0036263.t001
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disrupted SPIB site or increased due to enhanced binding of
TFAP2A and a novel AP1 site.
SNP344 status and MDM2 expression levels
To assess the potential impact of SNP344 genotype on MDM2
expression, we analysed MDM2 mRNA levels in leukocytes from a
subgroup of 215 healthy young males by qPCR. No difference in
MDM2 expression level between individuals harbouring the
SNP344AA (n= 1), 344TA (n= 10) or 344TT (n= 204) genotypes
was recorded (p.0.5 Figure 2A).
Since the SNP344A-variant resides on the SNP309T allele, we
performed separate sub-group analyses restricted to individuals
harbouring the SNP309TG (n= 101) or 309TT (n= 75) genotype.
No difference in MDM2 expression level related to SNP344 status
was recorded in any of these subgroups (p.0.4)
Since one may assume that the SNP344 status only affects the
MDM2 expression from promoter P2, in which the SNP is
localised, and that the effect of this SNP may be masked in assays
analysing the total MDM2 expression levels, we performed similar
qPCR experiments as described above but specific for mRNA
originating from promoter P2. No association between SNP344
status and promoter P2 specific expression was observed (p.0.5).
SNP344 status and cancer risk
In order to evaluate the potential impact of SNP344 status on
cancer risk, we compared the frequency of SNP344 variants
among ovarian (n= 1,927), breast (n = 1,271), endometrial
(n = 895) and prostate cancer patients (n = 641) to healthy controls
(n = 2,954). The results are summarised in Table 1. We found no
significant differences between the frequency of SNP344A in any
of the analysed cancer groups and the healthy controls.
Given that SNP344A was linked to the SNP309T-allele, as
described above, individuals harbouring the SNP309GG genotype
may be censored as non-informative with respect to the effect of
SNP344. We therefore assessed the impact of SNP344 on cancer
risk among individuals harbouring SNP309T-allele only
(SNP309TG or TT genotype; Table 3). We did not find any
association between SNP344 status and any of the cancer forms
analysing the SNP309TG and 309TT carriers separately or
combined (Figure 3).
SNP344 status and clinical parameters
We further assessed the potential impact of SNP344 status on
several clinical parameters among the patients included in the
case-control comparisons described above.
Data for age of onset of disease was available for all endometrial
(n = 895) and prostate cancer patients (n = 641) as well as large
sub-cohorts of breast (n = 1,173) and ovarian cancer patients
(n = 761). We found no effect of SNP344-status on age of onset in
either of the four cancer forms when comparing total patient
groups for each cancer form or subgroups stratified according to
SNP309-status (all p-values.0.15).
Among the breast cancer patients analysed, many were enrolled
in prospective studies aiming at identifying genetic mechanisms of
resistance to chemotherapy; n= 106 from two studies evaluating
either doxorubicin monotherapy or a combined 5-fluorouracil/
mitomycin regimens [16,17], while n= 201 were obtained from a
study randomizing between epirubicin and paclitaxel monother-
apy [18,19]. Thus, for these patients we had detailed records for
objective response to therapy in the neoadjuvant setting. SNP344
status did not affect response to either DNA damaging drugs
Table 2. Effect of SNP344 status on transcription factor
binding to MDM2 promoter P2.
Transciption factor Binding score
SNP344T SNP344A
TFAP2A 6.65 8.03
SPIB 4.68 -
AP1 - 6.20
doi:10.1371/journal.pone.0036263.t002
Figure 2. SNP344 and mdm2 expression. Box-plots representing log transformed relative levels of total MDM2 mRNA (A) and promoter P2
specific mRNA (B) in individuals harbouring the SNP344TT genotype versus the TA and AA genotypes.
doi:10.1371/journal.pone.0036263.g002
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(doxorubicin, mitomycin) or spindle poison (paclitaxel; p.0.1 for
all comparisons) in these studies, although the conclusion here may
be uncertain due to limited numbers of SNP344A-alleles observed.
The potential effect of SNP344 status on relapse-free or overall
survival could be assessed in these studies due to the limited
number of individuals harbouring the 344A-allele.
In a previous study, we found MDM2 SNP285 status to
correlate to stage in endometrial carcinomas [14]. Here, no
correlation between FIGO stage and SNP344 status was recorded.
(all p-values.0.3).
Discussion
MDM2 is an important factor regulating cellular homeostasis
through its close interactions with proteins like p53, pRB and
E2F1. Thus, MDM2 controls processes like growth arrest,
apoptosis and senescence, and MDM2 gene amplification and
enhanced translation have been observed in many tumour forms
[2,4,5,6,7].
Table 3. Distribution of SNP344 genotypes in cancer patients
and healthy controls, restricted to individuals carrying the
SNP309T-allele.
SNP344 (rs1196333) status
Cohort
Genotype
TT
Genotype
TA
Genotype
AA Total
n (%) n (%) n (%) n (%)
Ovarian cancer 1568 (94.2) 95 (5.7) 1 (0.1) 1664 (100)
Breast cancer 1022 (93.9) 63 (5.8) 3 (0.3) 1088 (100)
Endometrial
cancer
725 (93.5) 48 (6.2) 2 (0.3) 775 (100)
Prostatic cancer 502 (91.4) 46 (8.4) 1 (0.2) 549 (100)
Healthy controls 2421 (93.0) 180 (6.9) 1 (0.0) 2602 (100)
doi:10.1371/journal.pone.0036263.t003
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The importance of MDM2 expression in preventing cancer
development is further underlined by the finding that the MDM2
promoter P2 SNPs 285 and 309 both modulate transcription
factor binding and affect the risk of multiple cancer forms
[8,11,13,14]. While the exact mechanism of transcription
initiation from the MDM2 promoter P2 is not known, this
promoter is activated in response to cellular stress, and in addition
to Sp1, P2 harbours binding sites for multiple transcription factors
including p53, the estrogen receptor, AP1 [8,14] as well as several
others (prediction by the JASPAR database; data not shown).
SNP344T.A is the third MDM2 promotor P2 polymorphism.
Contrasting SNP285C, which is located on the SNP309G allele,
SNP344A resides on the SNP309T allele. Here, we performed in
silico prediction evaluating transcription factor binding strength
and determined the effect of SNP344 status on MDM2 transcript
levels in lymphocytes. While SNP344 was found to affect binding
of the transcription factors TFAP2A, SPIB and AP1, no effect of
SNP344 status on MDM2 transcription was recorded. Important-
ly, assessing the distribution of a SNP344 in a large cohort of
healthy individuals and among patients suffering from ovarian,
breast, endometrial and prostate cancer, we detected no
differences with respect to SNP344 distribution between healthy
individuals and cancer patients. While our study included a limited
number of cancer forms, for three of these cancers (breast, ovary
end endometrium) the SNP285C variant has previously been
shown to affect individual risk in the same ethnic population
[13,14]. Thus, these malignancies represent suitable cancer forms
to detect any potential effects of SNP344 status on disease risk.
Contrasting the SNP285G.C polymorphism which is detected
among Caucasians only [13], SNP344A, similar to SNP309G,
seems to be an ancient polymorphism that is also present among
Africans. Interestingly, the distribution of the SNP309G variant
allele, but also SNP344A, seems to vary across different ethnic
groups. While the frequency of the SNP309G allele varies from
,10% in Africans to ,40% in Caucasians and ,50% in Asians
[12], the frequency of the SNP344A allele is about 18% in Africans
but 3% only in Caucasians. This difference in ethnic distribution,
taken together with the rapid spread of the young SNP285C
polymorphism among Caucasians [20], indicates that all three
MDM2 promoter P2 polymorphisms may be subject to evolutionary
selection under different living conditions. Thus, further investiga-
tions elucidating potential impact of SNP344 on biological function
other than the cancer forms reported here may be warranted.
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